Table 5 Toxicity of neoadjuvant chemo/radiotherapy trials
Author | Drug | Diarrhea 3°4° (%) | Postop complic (%) | AL (%) |
|---|---|---|---|---|
Minsky ‘99 (Minsky et al, 1999) | CPT-11 | 18 | — | — |
Mehta ‘03 (Mehta et al, 2003) | CPT-11, 5-FU | 28 | 38# | 6 |
Mitchell ‘03 (Mitchell et al, 2003) | CPT-11, 5-FU | 27 | — | — |
Dotor ‘04 (Dotor et al, 2004) | CPT-11, 5-FU | 14 | — | — |
Levine ‘04 (Levine et al, 2004) | CPT-11, 5-FU | 3 | — | — |
Hofheinz ‘05 (Hofheinz et al, 2005) | CPT-11, CAP | 50–75* | 47 | 7 |
Klautke ‘05 (Klautke et al, 2005) | CPT-11, 5-FU | 32 | 14 | 9 |
Voelter ‘06 | CPT-11 | 24 | 27 | 6 |
Minsky ‘93 (Minsky et al, 1993) | 5-FU | 17 | 45 | 18 |
Rödel ‘00 (Rodel et al, 2000) | 5-FU | 23 | 28 | 18 |
Sauer ‘04 (Sauer et al, 2004) | 5-FU | 12 | 36 | 11 |
Bosset ‘04 (Bosset et al, 2004) | ∅/5-FU® | 17/34** | 22/23 | — |
Marijnen ‘02 (Marijnen et al, 2002) | ∅ | 14** | 48 | 11 |
SRCT ‘97 (Swedish Rectal Cancer Trial, 1997) | ∅ | — | 44 | 11 |
